Animal studies have shown a correlation between gut microbes and metabolic pathways for blood pressure regulation, but few epidemiological studies collect data on the same body microbiome and metabolomics.
Recently, researchers in the non-use of antihypertension drugs (30-69 years of age, 54% of women) in the leading cardiovascular journal Hypertension analyzed the effects of antihypertension therapy, assessed multivariate adjusted factors (e.g. diet, physical activity, smoking and kidney function), and gut bacteriosum index (16S rRNA (RNA), N The cross-sectional correlation between the plasma metabolites (liquid chromatography-mass spectrometry, N-434) and systolic pressure (SBP, mean value s.126.0 (17.4) mmHg) and espressuration (DBP .80.7 (10.7) mmHg).
the researchers found that the overall microbiome assessed through the main coordinate analysis was affected by SBP and DBP (multiple ANOVA, P.lt;0.05).
to illustrate the strong correlation between metabolites, the researchers first assessed metabolite changes from the main component analysis and found lipid metabolites and SBP (linear regression coefficient of 95% CI:2.2 3 (0.72-3.74) mmHg) and DBP (1.72 (0.81-2.63) mmHg) are positively related.
of the 1,104 individual metabolites, 34 and 39 metabolites were positively correlated with SBP and DBP (error detection rate- adjusted linear model P.lt;0.05), including lyphosphate, palm esters, diphthalates, 8 phosphates, 4 acrylamides, and 2 phosphatidyltin.
subsequent pathway analysis showed that long-chain saturation of carnitine, phosphatidyl inositol, and phospholipid metabolism pathways were associated with SBP and DBP (error detection rate-adjusted Fisher accurately tested P.lt;0.05).
results of this study suggest that the potential role of microbiomes and metabolites in blood pressure regulation requires follow-up in prospective and clinical studies.